Albert Dickan, MD

Dr Dickan is a fourth-year psychiatry resident at Creighton University.

Articles by Albert Dickan, MD

Safety and Efficacy of Intranasal Esketamine for Major Depressive Disorder and Treatment-Resistant Depression

ByNick Ratzloff, DO,Ayse K. Coskun, MD,Kari Wolatz, MD,Albert Dickan, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

June 15th 2026

Meta-analysis finds intranasal esketamine boosts remission in MDD and TRD fast, but side effects and short trials leave long-term questions.

Evaluating Glucagon-Like Peptide-1 Receptor Agonists and Mental Health Outcomes

ByMasha Impallaria, MD,Caitlin Leconte, MD,Irina Matsneva, MD,Albert Dickan, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

May 11th 2026

Large meta-analysis finds GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity.

Comparing SSRI Treatment and DBT for Managing Suicidality in Patients With Borderline Personality Disorder

ByLior Hilsenrath, MD,Orrin Chambers, DO,Kaamil Abid, MD,Albert Dickan, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

March 5th 2026

New RCT shows DBT cuts suicidal crises and self-harm in borderline personality disorder more than SSRIs, though benefits fade after treatment.

Anticholinergic Burden and Its Effect on Cognition in Psychosis

ByNishi Modi, MD,Cyrus Abbaszadeh, MD,Justin Allen, MD,Albert Dickan, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

January 12th 2026

Research reveals that reducing anticholinergic burden can significantly enhance cognitive function in patients with psychosis, offering new treatment insights.

Xanomeline-Trospium as a Novel Agent for Treatment of Psychosis in Schizophrenia

ByCaitlin Leconte, MD,Albert Dickan, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

February 17th 2025

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

Exploring the Role of Brexpiprazole in Alzheimer Dementia Agitation

ByJustin Allen, MD,Albert Dickan, MD,Jesse Woo, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

January 16th 2024

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

Latest Updated Articles

Exploring the Role of Brexpiprazole in Alzheimer Dementia Agitation
January 16th 2024
Comparing SSRI Treatment and DBT for Managing Suicidality in Patients With Borderline Personality Disorder
March 5th 2026